Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Hepatocellular 28Carcinoma, Non-Small-Cell Lung 23Lung Neoplasms 17Biliary Tract Neoplasms 13Small Cell Lung Carcinoma 12Cholangiocarcinoma 12Triple Negative Breast Neoplasms 8Breast Neoplasms 8Neoplasms 6Neoplasm Metastasis 5Liver Neoplasms 5Urinary Bladder Neoplasms 4Stomach Neoplasms 4Carcinoma 4Pancreatic Neoplasms 3Non-Muscle Invasive Bladder Neoplasms 3Gallbladder Neoplasms 3Colorectal Neoplasms 3Adenocarcinoma Of Esophagus 3Pathologic Complete Response 2Ovarian Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Bile Duct Neoplasms 2Advanced Biliary Tract Cancer 2Adenocarcinoma of Lung 2Adenocarcinoma 2Vaccinia 1SCLC, Limited Stage 1Resectable Intrahepatic Cholangiocarcinoma 1

Interventions

durvalumab 1Surgical Procedures, Operative 1Radiotherapy 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × SCLC, Limited Stage × durvalumab × Clear all
NCT06371482 2024-06-17

Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)

Hebei Medical University Fourth Hospital

Phase 2 Recruiting
58 enrolled
Thoracic

SCLC, Limited Stage

Data powered by HemOnc (CC BY 4.0) Colophon âš¡